Самоконтроль гликемии в лечении сахарного диабета: все ли мы знаем о современных возможностях?

1. Botnariu G, Bulgaru-Iliescu D. Determinant factors of cardiovascular mortality in type 2 diabetic patients: literature review. Rom J Leg Med 2010; 18 (4): 309–14. DOI: 10.4323/rjlm.2010.309
2. Nickerson HD, Dutta S. Diabetic Complications: Current Challenges and Opportunities. J Cardiovasc Transl Res 2012; 5 (4): 375–9.
3. Ruigomez A, Rodrigues LA. Presence of diabetes related complication at the time of NIDDM diagnosis: an important prognostic factor. Eur J Epidemiol 1998; 14 (15): 439–45.
4. Martin S. Epidemiology of Complications and Total Treatment Costs from Diagnosis of Type 2 Diabetes in Germany. Exp Clin Endocrinol Diabetes 2007; 115 (4): 240–3. DOI: 10.1055/s-2007-970577
5. Massi-Benedetti M. The Cost of Diabetes in Europe – ­Type II: the CODE-2 Study. Diabetolody 2002; 45 (7): S1-4.
6. Schwartz SS, Epstein S, Corkey BE et al. A Unified pathophysiological construct of diabetes and its complications. Trends Endocrinol Metab 2017; 28 (9): 645–55. DOI: 10.1016/j.tem.2017.05.005
7. ADA Standards of Medical Care in Diabetes. Diabetes Care 2018; 41: S1-S156. 
8. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой, А.Ю.Майорова. 9-й вып. М., 2019.
9. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89.
10. Papatheodorou K, Papanas N, Banach M et al. Complications of Diabetes. J Diabetes Res 2016; 2016: 6989453.
11. McGeoch G, Derry S, Moore RA. Self-monitoringof blood glucose in type-2 diabetes: what is the evidence? Diabetes Metab Res Rev 2007; 23: 423–40.
12. Clar C et al. Self-monitoring of blood glucose in type 2 diabetes: systematic review. Health Technol Assess 2010; 14 (12): 6.
13. Майоров А.Ю., Мельникова О.Г., Филиппов Ю.И. Вопросы самоконтроля гликемии в практике лечения сахарного диабета. Справочник поликлинического врача. 2012; 12: 32–6.
14. Farmer A, Wade A, Goyder E et al. Impact of self monitoring of blood glucose in the management of patients with non-insulin treated diabetes: open parallel group randomised trial. BMJ 2007; 335: 13–8.
15. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Eur Heart J 2013; 34: 2436–44.
16. Davidson MB, Castellanos M, Kain D et al. The effect of self monitoring of blood glucose concentrations on glycated hemoglobin levels in diabetic patients not taking insulin: a blinded, randomized trial. Am J Med 2005; 118: 422–5.
17. Guerci B, Drouina P, Grangéb V et al. Self-monitoring of blood glucose significantly improves metabolic control in patients with type 2 diabetes mellitus: the Auto-Surveillance Intervention Active (ASIA) study. Diabetes Metab 2003; 29: 587–94.
18. Karter AJ, Ackerson LM, Darbinian JA et al. Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med 2001; 111 (1): 1–9.
19. Neisser K, Weber C, Wenzel H, Schneider B. Costs of self-measurement of blood glucose (SMBG) regarding morbidity and mortality in type 2 diabetes in a reality of care setting (The ROSSO study No 6). The European Association for the Study of Diabetes. Abstract Volume 42st Annual Meeting, Copenhagen, Malmoe. 2006; p. 141.
20. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003; 163: 1306–16.
21. Pappas C, Kandaraki EA, Tsirona S. Postprandial dysmetabolism: too early or too late? Hormones 2016; 15: 321–44.
22. Shafiee G, Mohajeri-Tehrani M, Pajouhi M, Larijani B. The importance of hypoglycemia in diabetic patients. J Diabetes Metab Disord 2012; 11: 17. DOI: 10.1186/2251-6581-11-17
23. Briscoe VJ, Davis SN. Hypoglycemia in Type 1 and Type 2 Diabetes: Physiology, Pathophysiology, and Management. Clin Diabetes 2006; 24 (3): 115–21.
24. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes. Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28 (12): 2948–61.
25. ORIGIN Trial Investigators, Gerstein H, Yusuf S et al. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008; 155: 26–32.
26. Тимофеев А.В., Древаль Р.О. Глюкометры: цена точности. Эндокринология/кардиология. 2012; 12  (1; Спецвып.): 1–7. https://docplayer.ru/35458495-Glyukometry-cena-tochnosti.html
27. Freckmann G, Haug C, Heinemann L. Blutzuckerselbstmessung heute: Sindalle Geräte gleich. Diabetes Stoffwechsel Herz 2011; 20 (4): 235–41.
28. International Organization for Standardization. International Standard EN ISO 15197:2013. In Vitro diagnostic test systems: Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. Second Edition 2013-05-15. International Organization for Standardization, 2013.
29. Контур Плюс. Руководство пользователя. Асцензия, 2013. 
30. Dunne N, Viggiani MT, Pardo S et al. Accuracy Evaluation of CONTOUR®PLUS Compared With Four Blood Glucose Monitoring Systems. Diabetes Ther 2015; 6 (3): 377–88.
31. Yakaryılmaz FD, Öztürk ZA. Treatment of type 2 diabetes mellitus in the elderly. World J Diabetes 2017; 15; 8 (6): 278–85. DOI: 10.4239/wjd.v8.i6.278

Е.В. Бирюкова1, Н.М. Платонова2

1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр эндокринологии», Москва, Россия